Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide and Dexamethasone for BTK inhibitor–relapsed/refractory or intolerant mantle cell lymphoma
2018-000540-25Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, lenalidomide and dexamethasone in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: 12-month overall survival. Started Jun 2021; status: completed.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2018-000540-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000540-25.